摘要
目的 探讨黄芪总苷的抗肿瘤作用及其作用机制。方法 采用小鼠肝癌 (HepA)和肉瘤 (S1 80 )两种小鼠移植瘤的动物模型 ,以瘤重抑制率作指标。体外采用人宫颈癌细胞株HeLa细胞 ,用MTT法测肿瘤细胞的生长 ,流式细胞术及TUNEL法检测细胞周期及细胞凋亡。结果 黄芪总苷显著抑制小鼠肝癌 (HepA)和肉瘤 (S1 80 )的生长 ;体外可显著抑制HeLa细胞的生长 ,使细胞周期阻滞于G0 /G1 期 ,并诱导其凋亡。结论 黄芪总苷对小鼠肝癌 (HepA)与肉瘤(S1 80 )具有抑瘤作用。对HeLa细胞的生长有直接抑制作用。其抗肿瘤作用可能与细胞周期阻滞于G0 /G1
AIM To study the antitumor activity of astragalosides(AST) and its mechanism of action. METHODS By using two experimental models of hepatoma(HepA) and Sarcoma 180 in mice, the rate of inhibition of tumor weight AST on the growth of HepA and S180 tumor cells were tested. The growth inhibition of AST on Hela cells was detected by MTT assay. The effect of AST on cell cycle and apoptosis was analyzed by flow cytometry and TUNEL. RESULTS AST inhibited the growth of tumor cells of HepA and S180 in mice. AST inhibited the growth of Hela cell in concentration dependent manner with IC 50 of 80 4 mg·L -1 . Flow cytomety analgsis showed that G 0/G 1 phase rate was increased but S phase rate was decreased. The apoptosis rate of Hela cells treated with AST( 80 and 160 mg·L -1 ) was significantly higher than that of control. CONCLUSION AST can inhibit the growth of tumor cells of HepA and S180 in mice and the growth of HeLa cells in vitro . Causing cell cycle arrest and apoptosis is probably one of the mechanisms of antitumor effect by AST.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2003年第7期823-826,共4页
Chinese Pharmacological Bulletin
基金
国家新药基金资助课题
No 96 90 10 56 7
安徽省自然科学基金资助课题No 990 4 412 6
